Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16808475 | 1.00 | HDAC4 (0.41) | HDAC4TSHRPOLBALDH1A1ALOX15 | |
| SCHEMBL18802030 | 1.00 | HDAC4 (0.41) | HDAC4TSHRPOLBALDH1A1ALOX15 | |
| SCHEMBL27085623 | 1.00 | HDAC4 (0.41) | HDAC4TSHRPOLBALDH1A1ALOX15 | |
| SCHEMBL27085624 | 1.00 | HDAC4 (0.41) | HDAC4TSHRPOLBALDH1A1ALOX15 | |
| SCHEMBL30349456 | 0.87 | ALDH1A1 (0.43) | HDAC4TSHRPOLBALDH1A1ALOX15 | |
| SCHEMBL28364992 | 0.85 | TSHR (0.44) | HDAC4TSHRPOLBALDH1A1CYP2D6 | |
| SCHEMBL18186731 | 0.85 | TSHR (0.44) | HDAC4TSHRPOLBALDH1A1CYP2D6 | |
| SCHEMBL16808624 | 0.85 | TSHR (0.44) | HDAC4TSHRPOLBALDH1A1CYP2D6 | |
| SCHEMBL28365208 | 0.85 | TSHR (0.44) | HDAC4TSHRPOLBALDH1A1CYP2D6 | |
| SCHEMBL16808494 | 0.85 | TSHR (0.44) | HDAC4TSHRPOLBALDH1A1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11896593-B2 | Sulfamate derivative compounds for use in treating or alleviating a psychiatric disorder | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2024-02-13 | — | — | US | disclosed |
| EP-4211125-A1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER | Bio-Pharm Solutions Co., Ltd. (KR) | 2023-07-19 | — | — | EP | disclosed |
| US-20220218702-A1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2022-07-14 | — | — | US | disclosed |
| US-20220218702-A1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2022-07-14 | — | — | US | disclosed |
| WO-2022054987-A1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2022-03-17 | — | — | WO | disclosed |
| US-9937145-B2 | Sulfamate derivative compound for use in preventing or treating epilepsy | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2018-04-10 | — | — | US | disclosed |
| US-9937145-B2 | Sulfamate derivative compound for use in preventing or treating epilepsy | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2018-04-10 | — | — | US | disclosed |
| US-9834535-B2 | Sulfamate derivative compounds for use in treating or alleviating pain | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2017-12-05 | — | — | US | disclosed |
| US-9834535-B2 | Sulfamate derivative compounds for use in treating or alleviating pain | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2017-12-05 | — | — | US | disclosed |
| EP-2861571-B1 | PHENYLALKYL SULFAMATE COMPOUND AND MUSCLE RELAXANT COMPOSITION COMPRISING THE SAME | BIO-PHARM SOLUTIONS CO LTD (KR) | 2017-05-03 | — | — | EP | disclosed |
| US-20160318894-A1 | Sulfamate Derivative Compounds for Use in Treating or Alleviating Pain | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2016-11-03 | — | — | US | disclosed |
| US-20160318894-A1 | Sulfamate Derivative Compounds for Use in Treating or Alleviating Pain | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2016-11-03 | — | — | US | disclosed |
| US-20160310461-A1 | Sulfamate Derivative Compound for Use in Preventing or Treating Epilepsy | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2016-10-27 | — | — | US | disclosed |
| US-20160310461-A1 | Sulfamate Derivative Compound for Use in Preventing or Treating Epilepsy | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2016-10-27 | — | — | US | disclosed |
| US-9221783-B2 | Phenylalkyl sulfamate compound and muscle relaxant composition comprising the same | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2015-12-29 | — | — | US | disclosed |
| US-9221783-B2 | Phenylalkyl sulfamate compound and muscle relaxant composition comprising the same | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2015-12-29 | — | — | US | disclosed |
| US-20150266848-A1 | PHENYLALKYL SULFAMATE COMPOUND AND MUSCLE RELAXANT COMPOSITION COMPRISING THE SAME | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2015-09-24 | — | — | US | disclosed |
| US-20150266848-A1 | PHENYLALKYL SULFAMATE COMPOUND AND MUSCLE RELAXANT COMPOSITION COMPRISING THE SAME | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2015-09-24 | — | — | US | disclosed |
| WO-2015088273-A9 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING PAIN | BIO-PHARM SOLUTIONS, CO., LTD. (KR) | 2015-08-06 | — | — | WO | disclosed |
| WO-2015088273-A1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING PAIN | BIO-PHARM SOLUTIONS, CO., LTD. (KR) | 2015-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318894-A1 | Sulfamate Derivative Compounds for Use in Treating or Alleviating Pain | SULT2A1, STS, SULT1A1 | HDAC4 260/4885TSHR 4413/4885POLB 4662/4885 |
| US-20220218702-A1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER | SLC6A4, SLC6A3, SLC6A2 | HDAC4 80/4885TSHR 2322/4885POLB 4414/4885 |
| US-20150266848-A1 | PHENYLALKYL SULFAMATE COMPOUND AND MUSCLE RELAXANT COMPOSITION COMPRISING THE SAME | MYLK, MUSK, MYLK2 | HDAC4 665/4885TSHR 2872/4885POLB 4550/4885 |
| US-20160310461-A1 | Sulfamate Derivative Compound for Use in Preventing or Treating Epilepsy | STS, SULT2A1, GRIK5 | HDAC4 208/4885TSHR 4659/4885POLB 4592/4885 |
| US-11896593-B2 | Sulfamate derivative compounds for use in treating or alleviating a psychiatric disorder | SLC6A4, SLC6A3, SLC6A2 | HDAC4 80/4885TSHR 2322/4885POLB 4414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.